C07K 2319/035
Containing a signal for targeting to the external surface of a cell
Official title: containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
C07K2319/035 (Containing a signal for targeting to the external surface of a cell) appears on 408 US grants and 562 published applications in this corpus.
Search patents in C07K- Granted patents
- 408
- Published applications
- 562
- Assignees
- 357
- Inventors
- 1,249
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 6 | 0 |
| 1993 | 3 | 0 |
| 1994 | 6 | 0 |
| 1995 | 4 | 0 |
| 1996 | 5 | 0 |
| 1997 | 6 | 0 |
| 1998 | 13 | 0 |
| 1999 | 16 | 0 |
| 2000 | 11 | 0 |
| 2001 | 13 | 1 |
| 2002 | 3 | 6 |
| 2003 | 5 | 9 |
| 2004 | 2 | 5 |
| 2005 | 6 | 7 |
| 2006 | 4 | 9 |
| 2007 | 3 | 9 |
| 2008 | 1 | 12 |
| 2009 | 3 | 18 |
| 2010 | 8 | 20 |
| 2011 | 7 | 24 |
| 2012 | 10 | 20 |
| 2013 | 10 | 14 |
| 2014 | 19 | 19 |
| 2015 | 17 | 18 |
| 2016 | 11 | 25 |
| 2017 | 21 | 28 |
| 2018 | 21 | 45 |
| 2019 | 22 | 38 |
| 2020 | 31 | 36 |
| 2021 | 18 | 45 |
| 2022 | 25 | 33 |
| 2023 | 18 | 43 |
| 2024 | 23 | 37 |
| 2025 | 17 | 28 |
| 2026 | 17 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Tumor necrosis factor (TNF) receptor superfamily (TNFRSF) receptor-activating antibody fusion proteins with FCγR-independent agonistic activity (TNFRSF receptor-activating antibody fusion proteins with FCγR-independent agonistic activity; TRAAFFIAA)25 Aug 2026US 12,715,928 B2Julius-Maximilians-UniversitäT WüRzburg
- Methods and systems to secrete lignin-modifying enzymes and uses thereof11 Aug 2026US 12,703,877 B2The Board of Trustees of the Leland Stanford Junior University
- Gla domains as therapeutic agents14 Jul 2026US 12,678,481 B2Gladiator Biosciences, Inc.
- Plasmid encoding B-cell activating factor receptor (BAFF-R) and uses of same in the treatment and prevention of inflammatory diseases in fish7 Jul 2026US 12,673,979 B2Consejo Superior De Investigaciones Cientificas (Csic)
- Ligand discovery and gene delivery via retroviral surface display19 May 2026US 12,631,621 B2Massachusetts Institute of Technology
- Ligand discovery and gene delivery via retroviral surface display8 Oct 2026US 2026/0309700 A1Massachusetts Institute of Technology
- Conjugates for Targeted Cell Surface Editing3 Sep 2026US 2026/0258150 A1The Board of Trustees of the Leland Stanford Junior University
- Novel means to modulate nmda receptor-mediated toxicity20 Aug 2026US 2026/0242440 A1Fundamental Pharma GmbH
- Methods of treatment using igf-1 chimeric proteins6 Aug 2026US 2026/0226132 A1Silver Creek Pharmaceuticals, Inc.
- Engineered T Cells30 Jul 2026US 2026/0217855 A1Expression Therapeutics LLC
Most cited
By later US patents
- CDR grafted anti-CEA antibodies and their production238US 5,877,293 ACelltech Therapeutics Limited · 1999
- Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor164US 5,374,548 AGenentech, Inc. · 1994
- Adenovirus with modified binding moiety specific for the target cells150US 5,885,808 AImperial Cancer Research Technology, Ltd. · 1999
- Vaccine comprising a baculovirus produced influenza hemagglutinin protein fused to a second protein146US 5,858,368 AProtein Sciences Corporation · 1999
- Method for producing influenza hemagglutinin multivalent vaccines using baculovirus139US 5,762,939 AMg-Pmc, LLC · 1998